Publications
# designates co-first author(s)
Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis.
Kim PG, Hergott CB, Miller AP, Deik A, Boileau M, Bullock K, Pierce KA, Choy AH, Shin W, McConkey M, Loke J, Ryback BA, Trinh MN, Rutter JC, Yue H, Yoon H, Park P, Roy Burman SS, Vander Heiden MG, Fischer ES, Armstrong SA, Clish C, Ebert BL. Cell Chem Biol. 2026 Feb 19;33(2):183-197.e9. doi: 10.1016/j.chembiol.2026.01.006. Epub 2026 Feb 10.PMID: 41672066
Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.
Słabicki M, Park J, Nowak RP, Roy Burman SS, Pellman J, Zou C, Razumkov H, Carreiro J, Rastogi S, Goldstein A, Nagiec MM, Donovan KA, Che J, Hunkeler M, Geng Q, Hsu CL, Lakshminarayan M, Shu C, Zon RL, Kozicka Z, Park PMC, Tsai JM, Yoon H, Jones LH, Sperling AS, Gray NS, Fischer ES, Ebert BL. Mol Cell. 2025 Aug 21;85(16):3184-3201.e14. doi: 10.1016/j.molcel.2025.07.019.PMID: 40845806
Unveiling the hidden interactome of CRBN molecular glues.
Baek K, Metivier RJ, Roy Burman SS, Bushman JW, Yoon H, Lumpkin RJ, Ryan JK, Abeja DM, Lakshminarayan M, Yue H, Ojeda S, Xiong Y, Che J, Verano AL, Schmoker AM, Gray NS, Donovan KA, Fischer ES. Nat Commun. 2025 Jul 24;16(1):6831. doi: 10.1038/s41467-025-62099-w.PMID: 40707481
Template-assisted covalent modification underlies activity of covalent molecular glues.
Li YD, Ma MW, Hassan MM, Hunkeler M, Teng M, Puvar K, Rutter JC, Lumpkin RJ, Sandoval B, Jin CY, Schmoker AM, Ficarro SB, Cheong H, Metivier RJ, Wang MY, Xu S, Byun WS, Groendyke BJ, You I, Sigua LH, Tavares I, Zou C, Tsai JM, Park PMC, Yoon H, Majewski FC, Sperling HT, Marto JA, Qi J, Nowak RP, Donovan KA, Słabicki M, Gray NS, Fischer ES, Ebert BL. Nat Chem Biol. 2024 Dec;20(12):1640-1649. doi: 10.1038/s41589-024-01668-4. Epub 2024 Jul 29.PMID: 39075252
Polymerization of ZBTB transcription factors regulates chromatin occupancy.
Park PMC, Park J, Brown J, Hunkeler M, Roy Burman SS, Donovan KA, Yoon H, Nowak RP, Słabicki M, Ebert BL, Fischer ES. Mol Cell. 2024 Jul 11;84(13):2511-2524.e8. doi: 10.1016/j.molcel.2024.06.010.PMID: 38996460
Induced protein degradation for therapeutics: past, present, and future.
Yoon H, Rutter JC, Li YD, Ebert BL. J Clin Invest. 2024 Jan 2;134(1):e175265. doi: 10.1172/JCI175265.PMID: 38165043
TP63 fusions drive multicomplex enhancer rewiring, lymphomagenesis, and EZH2 dependence.
Wu G, Yoshida N, Liu J, Zhang X, Xiong Y, Heavican-Foral TB, Mandato E, Liu H, Nelson GM, Yang L, Chen R, Donovan KA, Jones MK, Roshal M, Zhang Y, Xu R, Nirmal AJ, Jain S, Leahy C, Jones KL, Stevenson KE, Galasso N, Ganesan N, Chang T, Wu WC, Louissaint A, Debaize L, Yoon H, Dal Cin P, Chan WC, Ho Sui SJ, Ng SY, Feldman AL, Horwitz SM, Adelman K, Fischer ES, Chen CW, Weinstock DM, Brown M. Sci Transl Med. 2023 Sep 20;15(714):eadi7244. doi: 10.1126/scitranslmed.adi7244. Epub 2023 Sep 20.PMID: 37729434
The human E3 ligase RNF185 is a regulator of the SARS-CoV-2 envelope protein.
Zou C, Yoon H, Park PMC, Patten JJ, Pellman J, Carreiro J, Tsai JM, Li YD, Roy Burman SS, Donovan KA, Gasser J, Sperling AS, Nowak RP, Fischer ES, Davey RA, Ebert BL, Słabicki M. iScience. 2023 May 19;26(5):106601. doi: 10.1016/j.isci.2023.106601. Epub 2023 Apr 8.PMID: 37095859
Exploring the target scope of KEAP1 E3 ligase-based PROTACs.
Du G, Jiang J, Henning NJ, Safaee N, Koide E, Nowak RP, Donovan KA, Yoon H, You I, Yue H, Eleuteri NA, He Z, Li Z, Huang HT, Che J, Nabet B, Zhang T, Fischer ES, Gray NS. Cell Chem Biol. 2022 Oct 20;29(10):1470-1481.e31. doi: 10.1016/j.chembiol.2022.08.003. Epub 2022 Sep 6.PMID: 36070758
BTBBCL6 dimers as building blocks for reversible drug-induced protein oligomerization.
Nitsch L, Jensen P, Yoon H, Koeppel J, Burman SSR, Fischer ES, Scholl C, Fröhling S, Słabicki M. Cell Rep Methods. 2022 Apr 13;2(4):100193. doi: 10.1016/j.crmeth.2022.100193. eCollection 2022 Apr 25.PMID: 35497498
Identification of Thieno[3,2-d]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.
Cho H*, Shin I*, Yoon H*, Jeon E, Lee J, Kim Y, Ryu S, Song C, Kwon NH, Moon Y, Kim S, Kim ND, Choi HG, Sim T. J Med Chem. 2021 Aug 26;64(16):11934-11957. doi: 10.1021/acs.jmedchem.1c00459. Epub 2021 Jul 29.PMID: 34324343
Small-molecule-induced polymerization triggers degradation of BCL6.
Słabicki M*, Yoon H*, Koeppel J*, Nitsch L, Roy Burman SS, Di Genua C, Donovan KA, Sperling AS, Hunkeler M, Tsai JM, Sharma R, Guirguis A, Zou C, Chudasama P, Gasser JA, Miller PG, Scholl C, Fröhling S, Nowak RP, Fischer ES, Ebert BL. Nature. 2020 Dec;588(7836):164-168. doi: 10.1038/s41586-020-2925-1. Epub 2020 Nov 18.PMID: 33208943
Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.
Teng M, Ficarro SB, Yoon H, Che J, Zhou J, Fischer ES, Marto JA, Zhang T, Gray NS. ACS Med Chem Lett. 2020 Apr 3;11(6):1269-1273. doi: 10.1021/acsmedchemlett.0c00111. eCollection 2020 Jun 11.PMID: 32551010
Targeted protein degradation as a powerful research tool in basic biology and drug target discovery.
Wu T, Yoon H, Xiong Y, Dixon-Clarke SE, Nowak RP, Fischer ES. Nat Struct Mol Biol. 2020 Jul;27(7):605-614. doi: 10.1038/s41594-020-0438-0. Epub 2020 Jun 15.PMID: 32541897
Structural complementarity facilitates E7820-mediated degradation of RBM39 by DCAF15.
Faust TB*, Yoon H*, Nowak RP, Donovan KA, Li Z, Cai Q, Eleuteri NA, Zhang T, Gray NS, Fischer ES. Nat Chem Biol. 2020 Jan;16(1):7-14. doi: 10.1038/s41589-019-0378-3. Epub 2019 Nov 4.PMID: 31686031
Identification of Novel Resorcinol Amide Derivatives as Potent and Specific Pyruvate Dehydrogenase Kinase (PDHK) Inhibitors.
Cho H, Shin I, Cho K, Yoon H, Yoo EK, Kim MJ, Park S, Lee IK, Kim ND, Sim T. J Med Chem. 2019 Sep 26;62(18):8461-8479. doi: 10.1021/acs.jmedchem.9b00565. Epub 2019 Sep 13.PMID: 31469962
Asymmetric Synthesis of (-)-6-Desmethyl-Fluvirucinine A₁ via Conformationally-Controlled Diastereoselective Lactam-Ring Expansions.
Moon H*, Yoon H*, Lim C, Jang J, Yi JJ, Lee JK, Lee J, Na Y, Son WS, Kim SH, Suh YG. Molecules. 2018 Sep 14;23(9):2351. doi: 10.3390/molecules23092351.PMID: 30223428
Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.
Yoon H, Shin I, Nam Y, Kim ND, Lee KB, Sim T. Eur J Med Chem. 2017 Jan 5;125:1145-1155. doi: 10.1016/j.ejmech.2016.10.050. Epub 2016 Oct 22.PMID: 27814560
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.
Yoon H, Kwak Y, Choi S, Cho H, Kim ND, Sim T. J Med Chem. 2016 Jan 14;59(1):358-73. doi: 10.1021/acs.jmedchem.5b01522. Epub 2015 Dec 22.PMID: 26652860
Give Now
Research Areas
Find out about the four types of research taking place at UT MD Anderson.